RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.-论文-万方医学网

第一作者： Peter,Brünker

第一单位： Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.

作者： Peter,Brünker ^[1] ; Katharina,Wartha ^[2] ; Thomas,Friess ^[2] ; Sandra,Grau-Richards ^[1] ; Inja,Waldhauer ^[1] ; Claudia Ferrara,Koller ^[1] ; Barbara,Weiser ^[2] ; Meher,Majety ^[2] ; Valeria,Runza ^[2] ; Huifeng,Niu ^[3] ; Kathryn,Packman ^[3] ; Ningping,Feng ^[3] ; Sherif,Daouti ^[3] ; Ralf J,Hosse ^[1] ; Ekkehard,Mössner ^[1] ; Thomas G,Weber ^[2] ; Frank,Herting ^[2] ; Werner,Scheuer ^[2] ; Hadassah,Sade ^[2] ; Cuiying,Shao ^[4] ; Bin,Liu ^[4] ; Peng,Wang ^[4] ; Gary,Xu ^[4] ; Suzana,Vega-Harring ^[2] ; Christian,Klein ^[1] ; Klaus,Bosslet ^[2] ; Pablo,Umaña ^[5]

作者单位： Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. ^[1] Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany. ^[2] Roche Pharma Research and Early Development, Roche Innovation Center New York, New York, New York. ^[3] Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China. ^[4] Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. pablo.umana@roche.com. ^[5]

医学主题词动物(Animals);抗体, 双特异性(Antibodies, Bispecific);抗体, 单克隆(Antibodies, Monoclonal);抗体亲和力(Antibody Affinity);抗肿瘤药(Antineoplastic Agents);细胞凋亡(Apoptosis);细胞系, 肿瘤(Cell Line, Tumor);疾病模型, 动物(Disease Models, Animal);剂量效应关系, 药物(Dose-Response Relationship, Drug);内肽酶类(Endopeptidases);成纤维细胞(Fibroblasts);明胶酶类(Gelatinases);人类(Humans);膜蛋白质类(Membrane Proteins);小鼠(Mice);蛋白质结合(Protein Binding);受体, TNF相关凋亡诱导配体(Receptors, TNF-Related Apoptosis-Inducing Ligand);丝氨酸内肽酶类(Serine Endopeptidases);肿瘤负荷(Tumor Burden);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.1158/1535-7163.MCT-15-0647

PMID 27037412

发布时间 2021-12-04

检索历史清除

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Molecular cancer therapeutics

相似文献

同项目论文

Molecular cancer therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Molecular cancer therapeutics

相似文献

同项目论文

Molecular cancer therapeutics

相关期刊

检索历史清除